02746nam 2200613 450 991081003370332120230803021710.01-118-47334-51-118-47330-21-118-47337-X(CKB)2550000001115767(EBL)1376942(OCoLC)857969529(MiAaPQ)EBC1376942(DLC) 2013019255(Au-PeEL)EBL1376942(CaPaEBR)ebr10756810(CaONFJC)MIL516102(EXLCZ)99255000000111576720130506h20132013 uy| 0engur|n|---|||||rdacontentrdamediardacarrierBlood and marrow transplantation long-term management prevention and complications /edited by Bipin N. SavaniChichester, West Sussex, UK :John Wiley & Sons,[2013]©20131 online resource (416 p.)Description based upon print version of record.1-118-47340-X 1-299-84851-6 Includes bibliographical references and index.section 1. Late effects concepts -- section 2. Management -- section 3. Supportive care for long-term survivors after HSCT. Currently more than 100,000 patients undergo blood and marrow transplantation (BMT) annually worldwide, a number which is steadily increasing. Long-term survival after BMT has improved significantly since its inception over 40 years ago, due to improved supportive care and early recognition of long-term complications. With broadening indications, more options for BMT, and improvement in survival, by 2020 there may be up to a million long-term survivors after BMT globally. Higher than average rates of second malignancies and cardiopulmonary, infectious, endocrine, and renal diseases, and bonHematopoietic stem cellsTransplantationBone marrowTransplantationHematopoietic stem cellsTransplantationComplicationsBone marrowTransplantationComplicationsLong-term care of the sickHematopoietic stem cellsTransplantation.Bone marrowTransplantation.Hematopoietic stem cellsTransplantationComplications.Bone marrowTransplantationComplications.Long-term care of the sick.616.02/774Savani Bipin N1593635MiAaPQMiAaPQMiAaPQBOOK9910810033703321Blood and marrow transplantation long-term management3913863UNINA